Alphatec Holdings (ATEC) Advances Lateral Sophistication

Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that the Company will introduce at the 2022 NASS Annual Meeting innovation designed to improve lateral surgery. The Company has applied learnings from Prone TransPsoas (PTPTM) and decades of lateral prowess to evolve both the Lateral TransPsoas (LTPTM) and the orthogonal Midline ALIFTM approaches with novel technology designed to advance treatment of L3 through S1, the most commonly treated levels in spine.

“Sophistication is in direct relation to the number of distinctions that are drawn to a subject, and for ATEC, our sophistication is lateral surgery,” asserted Pat Miles, Chairman and CEO. “We intend to be the standard bearer for lateral. By expanding its applications and innovating to improve outcomes regardless of position, ATEC is accelerating the shift toward less invasive spine care.”

Christopher Brown, M.D., Spine Surgeon and Assistant Professor of Neurosurgery and Orthopedic Surgery at Duke University, added, “What we started years ago has been improved with additional automated monitoring modalities as well as procedure-specific positioners and access systems. I prefer to address L3 to S1 anteriorly. I can now perform a streamlined procedure that couples ATEC LTP with the Midline ALIF approach to less invasively achieve the desired surgical goals without repositioning my patient.”

Vedat Deviren, M.D., Spine Surgeon and Professor of Orthopaedic Surgery at UCSF Medical Center, commented, “Spine surgery is evolving. In the past, we addressed every pathology with the same procedure. Now, innovation is more often enabling the pathology to dictate the approach. PTP and LTP avail unprecedented, single-position optionality.”

You May Also Be Interested In

• Trump Media & Technology (DJT) Declines 17% on Concerns Stockholders May Sell Shares
• Terex (TEX) Appoints Names R. Mark Cox as SVP Corporate Development
• Longeveron (LGVN) CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at AAIC